Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 9/20 | 0.62 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.62 |
| ▸ | JAK2 | O60674 | 2/20 | 0.62 |
| ▸ | JAK1 | P23458 | 2/20 | 0.62 |
| ▸ | TYK2 | P29597 | 2/20 | 0.62 |
| ▸ | STAT6 | P42226 | 7/20 | 0.56 |
| ▸ | SYK | P43405 | 3/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | WEE1 | P30291 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12301561 | 0.89 | JAK3 (0.66) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL2475230 | 0.89 | JAK3 (0.66) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL12301574 | 0.89 | JAK3 (0.73) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL12206772 | 0.89 | JAK3 (0.73) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL12301570 | 0.87 | JAK3 (0.63) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL12301582 | 0.87 | JAK3 (0.63) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL12301592 | 0.87 | JAK3 (0.68) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL2479931 | 0.87 | JAK3 (0.70) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL12207060 | 0.87 | JAK3 (0.62) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL2472223 | 0.86 | SYK (0.67) | JAK3IRAK4JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575153-B2 | Pyridine-3-carboxyamide derivative | KOWA COMPANY, LTD. (JP) | 2013-11-05 | — | — | US | claimed |
| EP-2380877-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | Kowa Company, Ltd. (JP) | 2011-10-26 | — | — | EP | claimed |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2011-09-29 | — | — | US | claimed |
| US-8575153-B2 | Pyridine-3-carboxyamide derivative | KOWA COMPANY, LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8575153-B2 | Pyridine-3-carboxyamide derivative | KOWA COMPANY, LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8575153-B2 | Pyridine-3-carboxyamide derivative | KOWA COMPANY, LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-2380877-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | Kowa Company, Ltd. (JP) | 2011-10-26 | — | — | EP | disclosed |
| EP-2380877-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | Kowa Company, Ltd. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2010061971-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | 興和株式会社 (JP) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | JAK3, JAK1, UACA | JAK3 1/4885IRAK4 128/4885JAK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.